:~ Cells were tested for interferon production using the superinduction method with polyriboinosinic, ribocytidilic acid (50 ~tg/ml), cycloheximide (10 ~tg/ml) and actinomycin D (1 Ixg/ml) as described by .
However, some other characteristics of the 22K factor distinguished it from known HulFN-13: it was stable in acid or SDS-containing buffers, but unlike HulFN-fl it had no affinity for immobilized zinc-chelate or Con A. Whereas classical HulFN-fl is active on cells of various nonhuman species, the 22K factor was found to be strictly species-specific, thereby resembling HulFN-? (Table 2) . In addition, when tested on different human cell types, it showed a remarkable cell specificity. It was inactive in HEp-2 and WISH cells which are sensitive to classical HuIFN-fl, as well as to HuIFN-~ and -y. It also failed to act in certain disomic and trisomic cells which were highly sensitive to HuIFN-fl.
In view of these data we investigated more closely why the antiviral effect of the 22K factor is neutralizable by anti-HuIFN-fl. The possibility was considered that our antisera against HuIFN-fl also contained antibodies against various other proteins, including perhaps the 22K protein. Sera from different sources (Table 1) were therefore used for the neutralization reactions. All sera caused neutralization; most significantly, a serum prepared against HuIFN-fl produced by Escherichia coli, expressing a plasmid-borne HuIFN-fl gene, also had neutralizing activity for the 22K factor, indicating that the cross-reactivity was not due to antibodies other than those directed against HuIFN-fl.
We also examined the affinity of the anti-HuIFN-fl antibody for the 22K protein. Neutralization reactions were carried out with a fixed concentration of antibody in each of the interferon dilutions before addition to the assay cells. Lowering of the concentration to limit amounts did not reveal consistent differences in the kinetics of interaction of the 22K factor and classical HuIFN-fl with the HuIFN-fl antibody (see Table t ). However, 22K failed to adsorb to a column of anti-HuIFN-fl antibody fixed on Sepharose beads, although this column did adsorb nearly 100% of classical HuIFN-fl and released this interferon on elution with acid. Furthermore, an antiserum prepared against the 22K factor by immunizing a rabbit was quite active in neutralizing the biological activity of the 22K factor, but was inactive against classical HuIFNfl. The latter two observations suggested that neutralization of the biological activity of the 22K factor by anti-HuIFN-fl might result from indirect interference of the antibody in the assay system.
There are several possible explanations for our data. Firstly, the 22K factor may be a novel HuIFN, different from known HuIFN-~, HulFN-fl and HulFN-y. Specifically, it may be a previously unknown subtype of HulFN-fl. This idea is supported by evidence for the existence of multiple genes for HulFN-fl as demonstrated by Sehgal &Sagar (1980) . However, according to Tavernier et al. (1981) there exists only one HuIFN-fl gene, thereby eliminating the possibility of pleomorphism in primary structure. Also, the 22K protein might share only a very few epitopes with HulFN-B. This does not necessarily imply stretches of identical amino acid sequence; areas with similar steric configuration would theoretically be sufficient to explain its relationship to HulFN-fl. A precedent for this is a protein described by Weissenbach et al. (1980) as HulFN-flz. This protein is obtained by translation in oocytes of a subclass of mRNA isolated from induced fibroblasts. In immunoprecipitation reactions this protein seems to be related to HulFN-fl, yet it is still not clear whether its biological activity is also serologically related to HulFN-fl.
Secondly, the 22K factor and classical HulFN-B might have the same primary structure but differ in glycosylation. This might explain different cell-and species-specificities as well as different affinities for adsorbents, but would less easily explain the lack of binding of the 22K factor to anti-HulFN-fl antibody, and the lack of cross-neutralization in reactions with anti-22K serum.
Thirdly, it might be a component of HulFN-y, since Yip et al. (1982) have demonstrated that mild treatment of HulFN-y (58K) with SDS, while destroying most of the biological activity, converts the residual material to two antiviral proteins of lower molecular weight: 20K and 25K. However, we consider this unlikely since neither derivative was reported to be neutralizable by anti-HulFN-p. Also, these materials have affinity for Con A while the 22K factor does not bind to Con A.
A very different possibility is that the 22K factor is not an interferon but an interferoninducing protein. In this case its antiviral activity in bioassays would result from production, by the assay cells, of HulFN-fl. Inclusion of antibody to HulFN-fl in the assay medium would neutralize the antiviral activity. This hypothesis has the advantage of being compatible with all the physicochemical and serological data presented here. Some further support for it is available from a comparison of the sensitivity of different human cell lines to the 22K factor and their capacity to produce HulFN-fl. Diploid cells and MG-63 cells are known to be good producers of HulFN-fl, and, as shown in Table 2 , are also very sensitive to the 22K factor. Also, the 22K-sensitive trisomic RoL cells were good producers, while the 22K-insensitive WISH and HEp-2 Cells were low producers. An exception to this parallelism were the trisomic LiR cells, which were relatively good producers of HulFN-fl but were poorly sensitive to the 22K factor.
Attempts to obtain direct evidence for the inducer hypothesis by demonstrating the production of HulFN-fl in diploid cell cultures after treatment with the 22K factor were always unsuccessful: supernatants and cell lysates of such cultures were always devoid of detectable amounts of HulFN-/L Thus, if our hypothesis is correct the amounts of interferon induced by the 22K factor would be small, but still sufficient to make the cells virus-resistant. Similar experiments with MG-63 cells yielded positive results, provided cycloheximide was included in the medium. This lead is currently being pursued in collaboration with a laboratory (that of Dr J. Content, Pasteur Institute, Brussels) experienced in detecting HulFN-fl mRNA in cells.
